American Society of Clinical Oncology (ASCO) Annual Meeting

BLU-222, an Investigational, Oral, Potent, and Highly Selective CDK2 Inhibitor, as Monotherapy in Patients With Advanced Solid Tumors and in Combination With Ribociclib and Fulvestrant in HR+/HER2− Breast Cancer